Abstract:We describe a multidisciplinary teamwork approach known as "Operation IDD Gene Team" developed by the Rose F. Kennedy Intellectual and Developmental Disabilities Research Center (RFK IDDRC) at the Albert Einstein College of Medicine. This initiative brings families affected by rare genetic diseases that cause intellectual and developmental disability together with physicians, basic scientists, and their trainees. At team meetings, family members share their child's medical and personal history, physicians describe the broader clinical consequences of the condition, and scientists provide accessible tutorials focused on the fundamental biology of relevant genes. When appropriate, possible treatment approaches are also discussed. The outcomes of team meetings have been overwhelmingly positive, with families not only expressing deep gratitude, but also becoming empowered to establish foundations dedicated to their child's specific condition. Physicians, and in particular the scientists and their trainees, have gained a deeper understanding of challenges faced by affected families, broadening their perspective on how their research can extend beyond the laboratory. Remarkably, research by the scientists following the Gene Team meetings have often included focus on the actual gene variants exhibited by the participating children. As these investigations progress and newly created foundations expand their efforts, national as well as international collaborations are forged. These developments emphasize the importance of rare diseases as windows into previously unexplored molecular and cellular processes, which can offer fresh insights into both normal function as well as more common diseases. Elucidating the mechanisms of and treatments for rare and ultra-rare diseases thus has benefits for all involved—families, physicians, and scientists and their trainees, as well as the broader medical community. While the RFK IDDRC's Operation IDD Gene Team program has focused on intellectual disabilities affecting children, we believe it has the potential to be applied to rare genetic diseases impacting individuals of any age and encompassing a wide variety of developmental disorders affecting multiple organ systems.

Gene-based therapeutics for rare genetic neurodevelopmental psychiatric disorders

Current and Future Prospects for Gene Therapy for Rare Genetic Diseases Affecting the Brain and Spinal Cord

Gene Therapy for Genetic Syndromes: Understanding the Current State to Guide Future Care

Gene therapy for CNS disorders: modalities, delivery and translational challenges

Using team-based precision medicine to advance understanding of rare genetic brain disorders

When rare meets common: Treatable genetic diseases are enriched in the general psychiatric population

Next-generation strategies for gene-targeted therapies of central nervous system disorders: A workshop summary

Next-Generation Therapeutics for Rare Genetic Disorders

Genome-wide Mendelian randomization identifies actionable novel drug targets for psychiatric disorders

Bioinformatics in Psychiatric Genetics

Leveraging the Genetics of Psychiatric Disorders to Prioritize Potential Drug Targets and Compounds

Genetic Treatment Approaches in Rare Pediatric Diseases

Gene therapy for neurotransmitter‐related disorders

Insights into Pathogenesis, Techniques for Variant Identification, and Therapeutic Approaches

Navigating Neurogenetics for Child and Adolescent Psychiatry Practice

CRISPR-Based Gene Editing Techniques in Pediatric Neurological Disorders

New directions in psychiatric drug development: promising therapeutics in the pipeline

An integrated clinical approach to children at genetic risk for neurodevelopmental and psychiatric conditions: interdisciplinary collaboration and research infrastructure

Advancing Mental Health Research Through Strategic Integration of Transdiagnostic Dimensions and Genomics

Nanoparticle-based Gene Therapy for Neurodegenerative Disorders

BrainSeq: Neurogenomics to Drive Novel Target Discovery for Neuropsychiatric Disorders